MX2021004114A - Anticuerpos dirigidos contra leucotoxinas de staphylococcus aureus. - Google Patents

Anticuerpos dirigidos contra leucotoxinas de staphylococcus aureus.

Info

Publication number
MX2021004114A
MX2021004114A MX2021004114A MX2021004114A MX2021004114A MX 2021004114 A MX2021004114 A MX 2021004114A MX 2021004114 A MX2021004114 A MX 2021004114A MX 2021004114 A MX2021004114 A MX 2021004114A MX 2021004114 A MX2021004114 A MX 2021004114A
Authority
MX
Mexico
Prior art keywords
staphylococcus aureus
directed against
antibodies directed
against staphylococcus
aureus leukotoxins
Prior art date
Application number
MX2021004114A
Other languages
English (en)
Inventor
Bret Sellman
Christine Tkaczyk
Qun Du
Melissa Damschroder
Andrea Minola
Davide Corti
Original Assignee
Medimmune Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Medimmune Llc filed Critical Medimmune Llc
Publication of MX2021004114A publication Critical patent/MX2021004114A/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies
    • C07K16/12—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria
    • C07K16/1267—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria
    • C07K16/1271—Immunoglobulins [IGs], e.g. monoclonal or polyclonal antibodies against material from bacteria from Gram-positive bacteria from Micrococcaceae (F), e.g. Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/02—Bacterial antigens
    • A61K39/085—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/569—Immunoassay; Biospecific binding assay; Materials therefor for microorganisms, e.g. protozoa, bacteria, viruses
    • G01N33/56911—Bacteria
    • G01N33/56938—Staphylococcus
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/30—Immunoglobulins specific features characterized by aspects of specificity or valency
    • C07K2317/33—Crossreactivity, e.g. for species or epitope, or lack of said crossreactivity
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/40—Immunoglobulins specific features characterized by post-translational modification
    • C07K2317/41—Glycosylation, sialylation, or fucosylation
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/51—Complete heavy chain or Fd fragment, i.e. VH + CH1
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/515—Complete light chain, i.e. VL + CL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/94—Stability, e.g. half-life, pH, temperature or enzyme-resistance

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Immunology (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Engineering & Computer Science (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Genetics & Genomics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • General Physics & Mathematics (AREA)
  • Biotechnology (AREA)
  • Virology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Cell Biology (AREA)
  • Pathology (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)

Abstract

La presente descripción está dirigida a anticuerpos de unión a leucotoxina y fragmentos de unión a antígenos de los mismos. Los anticuerpos y fragmentos pueden usarse, por ejemplo, para detectar leucotoxina y/o en métodos de tratamiento y prevención de infecciones por Staphylococcus aureus.
MX2021004114A 2018-10-09 2019-10-08 Anticuerpos dirigidos contra leucotoxinas de staphylococcus aureus. MX2021004114A (es)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201862743501P 2018-10-09 2018-10-09
PCT/US2019/055144 WO2020076790A1 (en) 2018-10-09 2019-10-08 Antibodies directed against staphylococcus aureus leukotoxins

Publications (1)

Publication Number Publication Date
MX2021004114A true MX2021004114A (es) 2021-07-16

Family

ID=68393067

Family Applications (1)

Application Number Title Priority Date Filing Date
MX2021004114A MX2021004114A (es) 2018-10-09 2019-10-08 Anticuerpos dirigidos contra leucotoxinas de staphylococcus aureus.

Country Status (11)

Country Link
US (2) US11059884B2 (es)
EP (1) EP3864040A1 (es)
JP (1) JP7459075B2 (es)
KR (1) KR20210080411A (es)
CN (1) CN113015745A (es)
AU (1) AU2019359207A1 (es)
BR (1) BR112021006704A2 (es)
CA (1) CA3115765A1 (es)
MX (1) MX2021004114A (es)
TW (1) TW202028232A (es)
WO (1) WO2020076790A1 (es)

Families Citing this family (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
AU2013341361A1 (en) * 2012-11-06 2015-06-04 Medimmune, Llc Antibodies to S. aureus surface determinants
WO2020023644A2 (en) 2018-07-24 2020-01-30 Medimmune, Llc Antibody directed against s. aureus clumping factor a (clfa)
WO2020076790A1 (en) 2018-10-09 2020-04-16 Medimmune, Llc Antibodies directed against staphylococcus aureus leukotoxins
TW202035443A (zh) 2018-10-09 2020-10-01 美商麥迪紐有限責任公司 抗金黃色葡萄球菌抗體的組合
CN113583119B (zh) * 2021-07-07 2023-05-02 西北农林科技大学 抗金黄色葡萄球菌的纳米抗体Nb56、应用及试剂盒
CN113493510A (zh) * 2021-07-07 2021-10-12 上海交通大学 一种牛源抗金黄色葡萄球菌LukD毒力因子的单链抗体及其制备和应用

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7658921B2 (en) 2000-12-12 2010-02-09 Medimmune, Llc Molecules with extended half-lives, compositions and uses thereof
JP2005538706A (ja) 2001-07-12 2005-12-22 ジェファーソン フーテ， スーパーヒト化抗体
US20040014194A1 (en) 2002-03-27 2004-01-22 Schering Corporation Beta-secretase crystals and methods for preparing and using the same
EP2126105A4 (en) 2007-02-20 2010-11-03 Anaptysbio Inc SOMATIC HYPERPERMUTATION SYSTEMS
BRPI1007005A2 (pt) 2009-01-29 2016-03-22 Medimmune Llc anticorpo isolado , ácido nucleico isolado n vetor, célula isolada , linhagem de célula isolada , composição farmacêutica, e, uso de um anticorpo anti-il-6
RU2677140C1 (ru) 2010-05-05 2019-01-15 Нью-Йорк Юниверсити Лейкоцидины staphylococcus aureus, терапевтические композиции и их применение
SG10201600899PA (en) 2011-02-08 2016-03-30 Medimmune Llc Antibodies that specifically bind staphylococcus aureus alpha toxin and methods of use
AU2013341361A1 (en) 2012-11-06 2015-06-04 Medimmune, Llc Antibodies to S. aureus surface determinants
CN112316135A (zh) 2012-11-06 2021-02-05 米迪缪尼有限公司 治疗金黄色葡萄球菌相关疾病的方法
JP6473746B2 (ja) * 2013-10-17 2019-02-20 アルサニス・バイオサイエンスズ・ゲゼルシャフト・ミト・ベシュレンクテル・ハフツング 交差反応性黄色ブドウ球菌抗体配列
JP6832709B2 (ja) 2014-05-16 2021-02-24 メディミューン，エルエルシー 新生児Ｆｃ受容体結合が改変されて治療および診断特性が強化された分子
TWI719938B (zh) 2014-06-19 2021-03-01 美商麥迪紐有限責任公司 多重細菌感染之治療
AU2016249837A1 (en) 2015-04-17 2017-09-28 Arsanis Biosciences Gmbh Anti-staphylococcus aureus antibody combination preparation
US20190077851A1 (en) 2015-10-30 2019-03-14 Bruno Francois Methods of using anti-alpha toxin antibody
WO2020023644A2 (en) 2018-07-24 2020-01-30 Medimmune, Llc Antibody directed against s. aureus clumping factor a (clfa)
TW202035443A (zh) 2018-10-09 2020-10-01 美商麥迪紐有限責任公司 抗金黃色葡萄球菌抗體的組合
WO2020076790A1 (en) 2018-10-09 2020-04-16 Medimmune, Llc Antibodies directed against staphylococcus aureus leukotoxins

Also Published As

Publication number Publication date
US11059884B2 (en) 2021-07-13
CA3115765A1 (en) 2020-04-16
WO2020076790A1 (en) 2020-04-16
EP3864040A1 (en) 2021-08-18
KR20210080411A (ko) 2021-06-30
CN113015745A (zh) 2021-06-22
JP7459075B2 (ja) 2024-04-01
JP2022512646A (ja) 2022-02-07
US20210363229A1 (en) 2021-11-25
US11578119B2 (en) 2023-02-14
TW202028232A (zh) 2020-08-01
BR112021006704A2 (pt) 2021-08-10
US20200109190A1 (en) 2020-04-09
AU2019359207A1 (en) 2021-05-20

Similar Documents

Publication Publication Date Title
MX2021004114A (es) Anticuerpos dirigidos contra leucotoxinas de staphylococcus aureus.
PH12020551930A1 (en) Anti-sirpa antibodies and methods of use thereof
PH12019501973A1 (en) Anti-phf-tau antibodies and uses thereof
PH12020552229A1 (en) Il-11ra antibodies
EP4248996A3 (en) Anti-trem2 antibodies and methods of use thereof
JOP20200309A1 (ar) أجسام مضادة لـ il-11
EA201992546A1 (ru) Средства на основе антител к cd33
EA201991157A1 (ru) Доставка белков на основе бактерий, аттенуированных по вирулентности
MX2020010951A (es) Anticuerpos anti-hla-g y utilizacion de los mismos.
WO2016062722A8 (en) Combination
MX2018015184A (es) Métodos para el diagnóstico de infecciones bacterianas y virales.
EP4335874A3 (en) Anti-hla-g antibodies and use thereof
MX2017011019A (es) Prueba de susceptibilidad antimicrobiana e identificacion de bacterias.
EA202091130A1 (ru) Лиофилизованный препарат моноклонального антитела к транстиретину
PH12019500929A1 (en) Anti il-33 antibodies and uses thereof
MX2019015516A (es) Anticuerpos de union a il-1beta para el uso en el tratamiento del cancer.
MX2022014422A (es) Anticuerpos contra el sars-cov-2 y metodos de seleccion y uso de los mismos.
MY191346A (en) Compositions and methods for treating and preventing staphylococcus aureus infections
PH12018500887A1 (en) Anti-htra1 antibodies and methods of use thereof
TW201613575A (en) Treatment of polybacterial infections
MX2021005394A (es) Co-formulaciones de anticuerpos anti-gen de activacion de linfocitos 3 (anti-lag3) y anticuerpos anti-muerte programada-1 (anti-pd-1).
MX2020000367A (es) Inhibidores de rad51.
MX2021004173A (es) Combinaciones de anticuerpos dirigidos contra staphylococcus aureus.
MX2020013324A (es) Anticuerpos anti proteína reguladora de señales beta 1 (sirp-beta1) y métodos de uso de los mismos.
PH12021550332A1 (en) Anti-cd33 antibodies and methods of use thereof